CD28 and acute lymphoblastic leukemia: Prospective randomized trials comparing the results of anti-CD19 CAR T cells co-stimulated with 41BB or CD28 are lacking, so it is currently not possible to determine whether either offers advantages in terms of efficacy in R/R ALL.